Vascular endothelial growth factor (VEGF) and chronic graft-versus-host disease (cGVHD) in salivary glands of bone marrow transplant (BMT) recipients

Journal of Oral Pathology and Medicine

Volumn 33, Issue 1, 2004, Pages 13-16

  Napier Souza, Leandro ^a,b   Antunes Carneiro, Marcelo ^a   De Azevedo, Wellington Morais ^a   Santiago Gomez, Ricardo ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

Author keywords

GVHD; Salivary glands; VEGF

Indexed keywords

BIOTIN; PEROXIDASE; STREPTAVIDIN; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGE; ARTICLE; BIOPSY; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LICHEN PLANUS; LICHENOID ERUPTION; MALE; MUCOSA INFLAMMATION; NEUTROPHIL; NONBIOLOGICAL MODEL; PARENTERAL NUTRITION; PATHOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SALIVARY GLAND; SALIVARY GLAND DISEASE; SEX DIFFERENCE; STATISTICAL MODEL; STEM CELL; SURVIVAL RATE; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; LICHEN PLANUS, ORAL; LINEAR MODELS; MALE; NEUTROPHILS; PARENTERAL NUTRITION; PROPORTIONAL HAZARDS MODELS; SALIVARY GLAND DISEASES; SEX FACTORS; STEM CELLS; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0742271498     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00035.x     Document Type: Article

References (20)

1. Heimdahl A, Mattson T, Dahllöf G, Lönnqvist B, Ringdén O. The oral cavity as a port of entry for early infection in patients treated with Bone Marrow Transplantation. Oral Surg Oral Med Oral Pathol 1989; 68: 711-6.
2. Nagler RM, Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant 1999; 23: 1007-11.
3. Basara N, Blau IW, Willembacher W, Kiehl MG, Fauser AA. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant 2000; 25: S12-5.
4. Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs. salivary gland changes in lip biopsies in the diagnosis of chronic graft-versus-host disease. Arch Pathol Lab Med 1989; 113: 932-4.
5. Nakamura S, Hiroki A, Shinohara M, et al. Oral involvement in chronic graft-versus-host after allogenic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 86: 556-63.
6. Kolbinson DA, Schubert MM, Flournoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1988; 66: 130-8.
7. Senger DR, Galli SJ, Dvorak AM, Perruzzi C, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington) 1983; 219: 983-5.
8. Senger DR, van de Water L, Brown L, et al. Vascular permeability factor (VPF/VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24.
9. Pammer J, Weninger W, Mildner M, Burian M, Wojta J, Tschachler E. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in saliva of healthy individuals. J Pathol 1998; 186: 186-91.
10. Connoly DT, Heulbelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
11. Taichman NS, Cruchley AT, Fletcher LM, et al. Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 1998; 78: 869-75.
12. Brown LF, Yet K-T, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375-9.
13. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-39.
14. Nissen NN, Polverini PJ, Kock AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-52.
15. Paula AMB, Gomez RS. Immunolocalization of p53, glutathione-S-transferase, π and CD57 antigens oral leukoplakia. Anticancer Res 2001; 21: 379-85.
16. Shi SR, Cote RJ, Taylor CR. Antigen retrieval in immunohistochemistry: past, present and future. J Histochem Cytochem 1997; 45: 327-43.
17. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-62.
18. Gomez RS, Carneiro MA, Souza LN, et al. Oral recurrent human herpes virus infection and bone marrow transplantation survival. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 552-6.
19. Gale RP, Bortin MM, Van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
20. Carlens S, Ringd́n O, Remberg M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single-centre analysis. Bone Marrow Transplant 1998; 22: 755-61.